Guardant Health

213 ‒ Liquid biopsies and cancer detection | Max Diehn, M.D. Ph.D.

Peter Attia MD

One of the first companies in the liquid biopsy field, with an FDA-approved test used for genotyping advanced metastatic cancer patients to guide treatment decisions.